公开(公告)号：US20240083900A1

公开(公告)日：2024-03-14

申请号：US18036853

申请日：2021-11-12

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  Bin Ma ,  Isaac Marx ,  Jürgen Schulz ,  George Vandeveer ,  Robin Prince ,  Marta Nevalainen ,  TeYu Chen ,  Zain Yousaf ,  Martin Himmelbauer ,  Vatee Pattaropong ,  John Howard Jones ,  Edward Yin-Shiang Lin ,  Felix Gonzalez Lopez de Turiso ,  Thomas Purgett ,  Andrew George Capacci ,  Simone Sciabola

IPC: C07D487/04 ,  C07D471/04 ,  C07D519/00

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D519/00

Abstract: Provided are compounds of Formula (I′): or pharmaceutically acceptable salts thereof, wherein the variables in the formula are as defined herein; and methods for their use and production.

公开(公告)号：US20210317103A1

公开(公告)日：2021-10-14

申请号：US17267631

申请日：2019-08-13

Applicant: BIOGEN MA INC.

Inventor： Felix Gonzalez Lopez de Turiso ,  Zhili Xin ,  Martin Himmelbauer ,  John H. Jones

IPC: C07D401/14 ,  C07D405/14

Abstract: Provided are compounds of Formula (I): Formula (I), including compounds of Formulas (II), (III), (IV), (V) and (VI), wherein X, R1, R2, R3, R4 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).

公开(公告)号：US20250152574A1

公开(公告)日：2025-05-15

申请号：US18837245

申请日：2023-02-13

Applicant: BIOGEN MA INC.

Inventor： Martin Himmelbauer ,  Felix Gonzalez Lopez de Turiso ,  John H. Jones ,  Edward Yin Shiang Lin ,  Robin Prince ,  Vatee Pattaropong ,  Zhili Xin ,  TeYu Chen ,  Nupur Bansal

IPC: A61K31/4709 ,  A61K31/438 ,  A61P25/28 ,  C07D221/20 ,  C07D401/12 ,  C07D491/107

Abstract: Provided are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.

公开(公告)号：US11814362B2

公开(公告)日：2023-11-14

申请号：US17253269

申请日：2019-06-26

Applicant: BIOGEN MA INC.

Inventor： Felix Gonzalez Lopez de Turiso ,  Michael Dechantsreiter ,  Zhili Xin ,  John H. Jones ,  Martin Himmelbauer

IPC: C07D401/14

CPC classification number: C07D401/14

Abstract: Provided are compounds of Formula (I): including compounds of Formulas (II), (III) and (IV), wherein X, R1, R2, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).

公开(公告)号：US20240327380A1

公开(公告)日：2024-10-03

申请号：US18019540

申请日：2021-08-05

Applicant: BIOGEN MA INC.

Inventor： Brian T. Hopkins ,  Isaac Marx ,  Jürgen Schulz ,  Harold George Vandeveer ,  Robin Prince ,  Marta Nevalainen ,  TeYu Chen ,  Zain Yousaf ,  Martin Himmelbauer ,  Vatee Pattaropong ,  John Howard Jones ,  Rab Gilfillan ,  Edward Yin Shiang Lin ,  Felix Gonzalez Lopez de Turiso ,  Bin Ma

IPC: C07D401/14 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/10

CPC classification number: C07D401/14 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/10

Abstract: Provided are compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R7, R8, R9, A1, A2, Q1, Q2, Q3, A, Z, m and n are as defined herein; pharmaceutical compositions comprising said compounds or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients; and methods of treating a disorder responsive to inhibition of Bruton's tyrosine kinase using said compounds, or pharmaceutically acceptable salts thereof, or said pharmaceutical compositions.

公开(公告)号：US11168095B2

公开(公告)日：2021-11-09

申请号：US16483790

申请日：2018-02-06

Applicant: BIOGEN MA INC.

Inventor： Felix Gonzalez Lopez de Turiso ,  Martin Himmelbauer ,  Michael J. Luzzio

IPC: C07D498/14

Abstract: Provided are compounds of Formulas (I′), (I), (II′) and (II), or pharmaceutically acceptable salts thereof, and methods for their use and production.

公开(公告)号：US20210115020A1

公开(公告)日：2021-04-22

申请号：US17253269

申请日：2019-06-26

Applicant: BIOGEN MA INC.

Inventor： Felix Gonzalez Lopez de Turiso ,  Michael Dechantsreiter ,  Zhili Xin ,  John H. Jones ,  Martin Himmelbauer

IPC: C07D401/14

Abstract: Provided are compounds of Formula (I): including compounds of Formulas (II), (III) and (IV), wherein X, R1, R2, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).

公开(公告)号：US20250161281A1

公开(公告)日：2025-05-22

申请号：US18832691

申请日：2023-01-23

Applicant: BIOGEN MA INC.

Inventor： Felix Gonzalez Lopez de Turiso ,  Martin Himmelbauer ,  Zhili Xin ,  Nupur Bansal ,  TeYu Chen ,  John Howard Jones ,  Edward Yin Shiang Lin

IPC: A61K31/439 ,  C07D451/04

Abstract: Provided are compounds of the Formula (I): (I), or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.

公开(公告)号：US11999715B2

公开(公告)日：2024-06-04

申请号：US17267631

申请日：2019-08-13

Applicant: BIOGEN MA INC.

Inventor： Felix Gonzalez Lopez de Turiso ,  Zhili Xin ,  Martin Himmelbauer ,  John H. Jones

IPC: C07D401/14 ,  C07D405/14

CPC classification number: C07D401/14 ,  C07D405/14

Abstract: Provided are compounds of Formula (I): Formula (I), including compounds of Formulas (II), (III), (IV), (V) and (VI), wherein X, R1, R2, R3, R4 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).

公开(公告)号：US20240109867A1

公开(公告)日：2024-04-04

申请号：US18377125

申请日：2023-10-05

Applicant: BIOGEN MA INC.

Inventor： Felix Gonzalez Lopez de Turiso ,  Michael Dechantsreiter ,  Zhili Xin ,  John H. Jones ,  Martin Himmelbauer

IPC: C07D401/14

CPC classification number: C07D401/14

Abstract: Provided are compounds of Formula (I):




including compounds of Formulas (II), (III) and (IV), wherein X, R1, R2, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).